JAK Inhibitors in RA: Applying Evidence-Based Strategies in Clinical Decision-making

**Registration for the ACR Convergence Program is required to participate in this live satellite. Please register at: https://www.rheumatology.org/Annual-Meeting/Registration

JAK inhibitors have established efficacy in the management of RA; however, clinicians and patients are uncertain about their place in therapy given recent safety concerns. Join us as expert faculty lead a robust discussion, highlighting the latest clinical trial and real-world evidence regarding JAK inhibitor efficacy and safety to help contextualize risks and apply practical mitigation strategies to comprehensive care plans.

This symposium is sponsored by Clinical Care Options, LLC and supported by a grant from Lilly USA, LLC. This is not an official program of the American College of Rheumatology.

Agenda

8:00 – Welcome

8:03 – Clinical Challenges in RA

8:08 – News You Can Use: The Latest JAK Inhibitor Efficacy and Safety Data in RA

8:18 – Putting It Into Context: Risks vs Benefits of JAK Inhibitors in RA

8:28 – Practical Strategies for Assessing and Managing Individual Patient Risk

8:45 – Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Vibeke Strand, MD, MACR, FACP

Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University
Biopharmaceutical Consultant
Palo Alto, California

Faculty
Vivian P. Bykerk, MD, FRCPC

Associate Professor of Medicine
Division of Rheumatology
Department of Medicine
Weill Cornell Medical Center
Director, Inflammatory Arthritis Center of Excellence
Rheumatology Attending
Department of Rheumatology
Hospital for Special Surgery
New York, New York

Program Overview
JAK inhibitors have established efficacy in the management of RA; however, clinicians and patients are uncertain about their place in therapy given recent safety concerns. Join us as expert faculty lead a robust discussion, highlighting the latest clinical trial and real-world evidence regarding JAK inhibitor efficacy and safety to help contextualize risks and apply practical mitigation strategies to comprehensive care plans.

Goal Statement
The goal of this educational program is to improve knowledge and competence among learners regarding the appropriate use of JAK inhibitors in rheumatoid arthritis to help patients attain low disease activity/remission and improved quality of life.

Target Audience
US- and OUS-based rheumatologists, excluding physicians located in the United Kingdom.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review recent efficacy and safety data for JAK inhibitor therapy in RA
  • Assess the benefits and risks of JAK inhibitor therapy for patients with RA based on patient comorbidities and risk factors
  • Incorporate practical management and risk mitigation strategies into comprehensive care plans for patients with RA receiving JAK inhibitor therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.